Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders and known risk factors

Competing Interest Statement

In the past 3 years, Dr. Kessler was a consultant for Datastat, Inc, Sage Pharmaceuticals, and Takeda. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. Dr. Kranzler is a member of an advisory board for Dicerna Pharmaceuticals and of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Dicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. Dr. Li is an employee of Janssen Research & Development, LLC, and shareholder in Johnson & Johnson, the parent company of the Janssen companies. Dr. Li declares that, except for income received from her primary employer, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. Dr. Stein has in the past 3 years been a consultant for Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Epivario, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Oxeia Biopharmaceuticals. Dr. Stein has stock options in Oxeia Biopharmaceuticals and Epivario. Dr. Grabe has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care. Dr. Andreassen is a consultant for HealthLytix, and received speaker's honorarium from Lundbeck and Sunovion. Dr Power is employed by and holds shares in BioMarin Pharmaceuticals. Michael O'Donovan and Michael Owen are supported by a collaborative research grant from Takeda Pharmaceuticals. That support did not contribute to the work described in this manuscript. Eugenio H Grevet has served in the speakers' bureau and the advisory board of Takeda (former Shire do Brasil) Pharmaceutical. Josep Antoni Ramos-Quiroga was on the speakers' bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogui, Lundbeck, Almirall, Braingaze, Sincrolab, Medice and Rubió in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogui, Bial, Medice and Eli- Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 5 years: Eli-Lilly, Lundbeck, Janssen- Cilag, Actelion, Shire, Ferrer, Oryzon, Roche, Psious, and Rubió. Christian Fadeuilhe has received fees to give talks for Shire, Ferrer, Italfarmaco and Otsuka in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Lundbeck, Otsuka and Ferrer. Vanesa Richarte was on the speakers' bureau and/or acted as consultant for Takeda and Rubió in the last 5 years. She also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Rubió, Shire, Takeda and Lundbeck. Miguel Casas was on the speakers' bureau and/or acted as consultant for Janssen-Cilag in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag. All other authors declare that they have no conflicts of interest.

Funding Statement

Statistical analyses were carried out on the NL Genetic Cluster Computer (http://www.geneticcluster.org) hosted by SURFsara and the Mount Sinai high performance computing cluster (http://hpc.mssm.edu), which is supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. This work was conducted in part using the resources of the Advanced Computing Center for Research and Education at Vanderbilt University, Nashville, TN. This work is supported by R01MH116269 (DMR) and R01MH121455 (DMR). Research reported in this publication was also supported by NIGMS of the National Institutes of Health under award number T32GM007347 (JK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University of North Carolina at Chapel Hill University of Oxford Emory University and Grady Research Oversight Committee University of Michigan IRB Medical Faculty Mannheim, Heidelberg University; Charité; Berlin; State Chamber of Physicians of Rhineland Palatinate Generic approval from the NHS National Research Ethics Service (approval letter dated 13 May 2016, Ref 16/NW/0274) National Taiwan University Hospital National Taiwan University Hospital National Taiwan University Hospital Danish Regional Ethics Committee "Clinical trials (IDs: NCT00044681, NCT00397033, NCT00412373, NCT00334126, NCT01193153, NCT00094926) conducted by Janssen Research & Development, LLC, institutional review board or human subjects board at each site; for healthy control samples from NINDS Human Genetics Repository, submitter of samples to NINDS is required to have a copy of the IRB-approved consent form for each subject on file by the submitter; prospective collection of normal control samples for research by BioIV was approved by Schulman IR. " Research Ethics Committee at the Karolinska Institute (#97-188) and Ministry of Health in Ukraine The QIMR Berghofer Medical Research Institute-Human Research Ethics Committee (QIMR Berghofer-HREC) Yale: Human Research Protection Program (HRPP); MUSC: Medical University of South Carolina Institutional Review Board for Human Research; Penn: University of Pennsylvania Office of Regulatory Affairs; McLean: McLean Hospital Institutional Review Board; UConn: University of Connecticut Institutional Review Board Yale: Human Research Protection Program (HRPP); MUSC: Medical University of South Carolina Institutional Review Board for Human Research; Penn: University of Pennsylvania Office of Regulatory Affairs; McLean: McLean Hospital Institutional Review Board; UConn: University of Connecticut Institutional Review Board New York State Psychiatric Institute IRB University of Utah IRB; Utah State Health Department IRB; Intermountain Health IRB The Ethics Committee for Genetic Studies of Kobe University and RIKEN

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes